NCT06500429View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

September 4, 2024

Study Completion Date

September 13, 2024

Conditions

Overweight and ObesityHealthy

Interventions

DRUG

NG101

NG101 20 mg BID

DRUG

Placebo

Placebo BID

DRUG

Semaglutide Injectable Product

Semaglutide 0.5 or 1 mg

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Neurogastrx, Inc.

All Listed Sponsors

lead

Neurogastrx, Inc.

INDUSTRY

NCT06500429 - A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist | Biotech Hunter | Biotech Hunter